Evidence map›Paper›PMID 41893368›Full record

ReviewMedicines (Basel, Switzerland)2026

Advances in Extracellular Matrix Metalloproteinases: Implications for Renal Cell Carcinoma Pathophysiology, Diagnostics, and Therapeutics.

Evangelia Krikou, Ioanna A Anastasiou, Panagiotis Sarantis, Hariklia Gakiopoulou, Irini Theochari, Dimitra Grigoriadou, Andreas C Lazaris, Eleftheria Lakiotaki

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicines (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Evangelia KrikouFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Building 10, Goudi, 11527 Athens, Greece.
Ioanna A AnastasiouDiabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Goudi, 11527 Athens, Greece.ORCID 0000-0002-7560-0575
Panagiotis SarantisMolecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-5848-7905
Hariklia GakiopoulouFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Building 10, Goudi, 11527 Athens, Greece.
Irini TheochariFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Building 10, Goudi, 11527 Athens, Greece.
Dimitra GrigoriadouFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Building 10, Goudi, 11527 Athens, Greece.
Andreas C LazarisFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Building 10, Goudi, 11527 Athens, Greece.ORCID 0000-0002-8118-7780
Eleftheria LakiotakiFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias Str., Building 10, Goudi, 11527 Athens, Greece.ORCID 0000-0002-2738-0192

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is a common tumor that heavily depends on extracellular matrix (ECM) remodeling, an essential process involved not only in normal tissue homeostasis but also in malignant growth. This article reviews the role of matrix metalloproteinases (MMPs, zinc-dependent endopeptidases) in matrix degradation and ECM reorganization in the setting of RCC. We focus on the specific role of MMP2, MMP7, and MMP9 in clear cell renal cell carcinoma (ccRCC) and major subtypes of RCC. Higher levels of these MMPs are associated with high-grade tumors, increased risk of metastasis, and poorer patient survival rates, indicating that they may have value as prognostic markers. This review also discusses how ECM composition and structure are altered in the tumor microenvironment (TME), thereby preventing cell interactions and promoting cancer growth. Finally, it compiles the existing studies to anticipate a future era in which MMPs could serve as effective prognostic biomarkers and potential treatment targets for RCC, with implications for improving diagnostic and therapeutic interventions targeting ECM remodeling to suppress cancer progression.

Indexed as

clear cell RCCextracellular matrixmatrix metalloproteinasesrenal cell carcinomatumor microenvironment

Identifiers

PMID41893368
PMCPMC13028108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.